Albany, NY -- (SBWIRE) -- 10/18/2018 -- Recombinant factor C assay is a type of pyrogen test that determines the presence of endotoxin substances. Recombinant factor C assay is a new alternative to various endotoxin tests such as limulus amebocyte lysate test. Recombinant factor C is the first component in the horseshoe crab clotting cascade that is activated by endotoxin. Recombinant factor C assay is activated by endotoxin binding, which results in the generation of flurogenic compounds. Pyrogens are substances that cause fever after administering an injection. Increase in body ache and body temperature are harmful reactions caused due to injection of pyrogens in the body. Drug manufacturers employ a process of recombinant factor C assay to determine if the manufactured vaccine or drug is likely to cause fever on administration. Various countries are focused on preventing infectious diseases to reduce the associated health care costs, this in turn is expected to increase the demand for health care facilities. Moreover, governments are focusing on pyrogen-free medical devices and pharmaceuticals for patients.
Report Overview @ https://www.transparencymarketresearch.com/recombinant-factor-c-assay-market.html
Factors such as elimination of false-positive glucan reactions, no animal are used for testing, and predictable and reliable assay performance are the factors driving the recombinant factor C assay market during the forecast period. Globally increasing health care awareness, growing number of pharmaceutical and biotechnology companies, and shifting focus of patients toward the treatment of chronic and lifestyle diseases is propelling the recombinant factor C assay market. Increasing research & development activities in the health care industry, rise in the number of new drug approvals, and growing incidences of chronic diseases are boosting the market. Increasing production of cosmetic products supports the expansion of the recombinant factor C assay market owing to the cosmetic products need to be tested for pyrogens. Increasing inclination toward animal-free detection tests, rising government initiatives for the prevention of diseases to curb health care costs, and rise in pharmaceutical outsourcing are projected to boost the demand for recombinant factor C testing. However, high entry barrier for new market entrants and small players are some of the restraining factors of the global recombinant factor C assay market.
Request Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=36044
The global recombinant factor C assay market can be segmented based on product type, end-user, and region. In terms of product type, the market can be categorized into routine assay, inhibition/enhancement (INH/ENH), reference standard endotoxin/ control standard endotoxin (RSE/CSE), and initial qualification (INT. QUAL). Based on end-user, the market can be divided into pharmaceuticals industry, biotechnology industry, medical devices industry, and others.
Geographically, the recombinant factor C assay market can be divided into Asia Pacific, Latin America, Europe, North America, and Middle East & Africa. North America accounted for a dominant share of the market in 2016 due to the presence of key players in the region,, rising technological advancements in research & development activities, and growing health care awareness. Europe was the second most dominant region in 2016 owing to company initiatives. In September 2016, Merck joined DiViNe Project—a European consortium of six companies that work to address challenges faced in the development, manufacturing process, and delivery of vaccines. The market in Asia Pacific is anticipated to expand during the forecast period owing to increasing focus of key companies to expand their presence in the region, to meet growing demand. Moreover, increasing government initiatives for health care awareness in the region also boosts the market. Rising patient population diagnosed with chronic diseases in the Asia Pacific region propels the market in the region. The market in Latin America and Middle East & Africa is anticipated to expand during the forecast period owing to increasing government initiatives.
Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=36044
Key players operating in the global recombinant factor C assay market include Hyglos GmbH, Lonza, and Hawaii Biotech Inc.
About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR's syndicated reports strive to provide clients to serve their overall research requirement.
Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com